Delivery Order 36F79719D0224-36C24525N0296
Award Date
1/7/25
Potential Completion Date
1/8/25
Potential Value
$77K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Horizon Therapeutics Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The $55,903.32 order is placed against Horizon's existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This delivery order will provide the VA with pegloticase injections to treat chronic gout in eligible veterans through...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a Delivery Order to Horizon Therapeutics USA Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The contract, with a potential value of $55,903.32, is a Firm Fixed Price order placed against Horizon Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The Delivery Order has an April 17, 2024 completion date and does not have a set-aside designation. Horizon...
This contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the United States Department of Veterans Affairs (VA). The contract, valued at $37,268.88, is a firm fixed-price delivery order placed by the VA's Veterans Integrated Service Network 5 (VISN 5) against the prime contractor Horizon Therapeutics USA, Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Horizon Therapeutics USA, Inc. is a global biotechnology...
The Department of Veterans Affairs Veterans Health Administration awarded a $131,372.30 firm fixed price delivery order to Horizon Therapeutics USA Inc., a foreign-owned for-profit organization, for the provision of KRYSTEXXA medication. This order was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has no set-aside designation. Horizon Therapeutics has a $18 million Blanket Purchase Agreement against the...
This is a $93,172.20 firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Horizon Therapeutics USA, Inc. for the drug KRYSTEXXA 8MG. The order was placed against Horizon's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which has an expiration date of August 2025. Horizon also holds an $18 million Blanket Purchase Agreement (BPA) against the same Pharmaceuticals and Drugs Schedule, covering the procurement of...
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that specializes in rare, autoimmune, and inflammatory disease treatments. The $74,667.32 firm fixed-price delivery order was placed against Horizon's existing Pharmaceuticals and Drugs (FSS-61-IB) Multiple Award Schedule contract with the General Services...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order for KRYSTEXXA 8MG to the prime contractor, Horizon Therapeutics USA, Inc. This order, valued at $74,537.76, was placed against Horizon's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The delivery order has an April 17, 2024 completion date and will provide the specialized orphan drug to VHA hospitals and clinics across the country...
The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a delivery order to Horizon Therapeutics USA Inc. for KRYSTEXXA 8MG, a specialty pharmaceutical product. The order, valued at $55,903.32, was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and did not have a set-aside designation. Horizon Therapeutics is a global biotechnology company that provides orphan drugs and specialty pharmaceuticals to support...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Horizon Therapeutics USA Inc. for the drug KRYSTEXXA 8MG/ML VIAL. The order is placed against Horizon's pre-existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The order has a firm fixed price of $74,537.76 and a completion date of May 31, 2024. Horizon Therapeutics USA Inc. is a global biotechnology...
This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc., a global biotechnology company, under the company's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The $37,268.88 award is for the delivery of KRYSTEXXA 8MG, a specialty medication used to treat chronic gout, to support healthcare services for veterans. This delivery order is placed against Horizon's $31.375 million...